[HTML][HTML] Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations
A Preto, J Gonçalves, AP Rebocho, J Figueiredo… - BMC cancer, 2009 - Springer
Background Thyroid carcinomas show a high prevalence of mutations in the oncogene
BRAF which are inversely associated with RAS or RET/PTC oncogenic activation. The …
BRAF which are inversely associated with RAS or RET/PTC oncogenic activation. The …
Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations
A Preto, J Gonçalves, AP Rebocho, J Figueiredo… - BMC Cancer, 2009 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: sec>< jats: title> Background</jats: title>< jats: p>
Thyroid carcinomas show a high prevalence of mutations in the oncogene BRAF which are …
Thyroid carcinomas show a high prevalence of mutations in the oncogene BRAF which are …
[PDF][PDF] Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations
A Preto, J Gonçalves, AP Rebocho, J Figueiredo… - BMC Cancer, 2009 - Citeseer
Background: Thyroid carcinomas show a high prevalence of mutations in the oncogene
BRAF which are inversely associated with RAS or RET/PTC oncogenic activation. The …
BRAF which are inversely associated with RAS or RET/PTC oncogenic activation. The …
Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations
A Preto, P Soares, M Sobrinho-Simões… - BMC Cancer …, 2009 - inis.iaea.org
[en] Thyroid carcinomas show a high prevalence of mutations in the oncogene BRAF which
are inversely associated with RAS or RET/PTC oncogenic activation. The possibility of using …
are inversely associated with RAS or RET/PTC oncogenic activation. The possibility of using …
Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations
A Preto, J Gonçalves, AP Rebocho… - BMC …, 2009 - pubmed.ncbi.nlm.nih.gov
Background Thyroid carcinomas show a high prevalence of mutations in the oncogene
BRAF which are inversely associated with RAS or RET/PTC oncogenic activation. The …
BRAF which are inversely associated with RAS or RET/PTC oncogenic activation. The …
[PDF][PDF] Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations
A Preto, J Gonçalves, AP Rebocho, J Figueiredo… - BMC Cancer, 2009 - academia.edu
Background: Thyroid carcinomas show a high prevalence of mutations in the oncogene
BRAF which are inversely associated with RAS or RET/PTC oncogenic activation. The …
BRAF which are inversely associated with RAS or RET/PTC oncogenic activation. The …
Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations
A Preto, J Goncalves, AP Rebocho, J Figueiredo… - BMC Cancer, 2009 - hero.epa.gov
Background: Thyroid carcinomas show a high prevalence of mutations in the oncogene
BRAF which are inversely associated with RAS or RET/PTC oncogenic activation. The …
BRAF which are inversely associated with RAS or RET/PTC oncogenic activation. The …
[HTML][HTML] Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations
A Preto, J Gonçalves, AP Rebocho, J Figueiredo… - BMC Cancer, 2009 - ncbi.nlm.nih.gov
Background Thyroid carcinomas show a high prevalence of mutations in the oncogene
BRAF which are inversely associated with RAS or RET/PTC oncogenic activation. The …
BRAF which are inversely associated with RAS or RET/PTC oncogenic activation. The …
[HTML][HTML] Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations
A Preto, P Soares, M Sobrinho-Simões, J Gonçalves… - BMC Cancer (Online …, 2009 - osti.gov
Thyroid carcinomas show a high prevalence of mutations in the oncogene BRAF which are
inversely associated with RAS or RET/PTC oncogenic activation. The possibility of using …
inversely associated with RAS or RET/PTC oncogenic activation. The possibility of using …
[PDF][PDF] Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations
A Preto, J Gonçalves, AP Rebocho, J Figueiredo… - BMC Cancer, 2009 - researchgate.net
Background: Thyroid carcinomas show a high prevalence of mutations in the oncogene
BRAF which are inversely associated with RAS or RET/PTC oncogenic activation. The …
BRAF which are inversely associated with RAS or RET/PTC oncogenic activation. The …